Published
This video covers key updates from the phase 3 AEGEAN trial presented at WCLC 2024 and ESMO 2024, focusing on perioperative durvalumab in resectable NSCLC and the expanded analysis of circulating tumor DNA (ctDNA) clearance during neoadjuvant treatment.
???? Stay informed with the latest evidence in immunotherapy and precision oncology.
#AEGEANTrial #Durvalumab #NSCLC #WCLC2024 #ESMO2024 #ctDNA #LungCancer #Immunotherapy
???? Stay informed with the latest evidence in immunotherapy and precision oncology.
#AEGEANTrial #Durvalumab #NSCLC #WCLC2024 #ESMO2024 #ctDNA #LungCancer #Immunotherapy
- Category
- Oncology
Be the first to comment
Up Next
-
17:15
Dario Trapani CSO Symposium ESMO 2024
-
KEYNOTE-671: Neoadjuvant & Adjuvant Pembrolizumab in Early-Stage NSCLC – Phase 3 Trial Results.
-
12:50
Rodrigo Lastra CSO Symposium ESMO 2024
-
14:55
Bishal Gyawali CSO Symposium ESMO 2024
-
04:24
GU oncology update from ESMO 2024
-
05:52
CASSANDRA: Neoadjuvant PAXG Versus mFOLFIRINOX for Resectable, Borderline Resectable PDAC
-
NEOTORCH Trial: Perioperative Toripalimab + Chemo in Resectable NSCLC – Phase 3 Results.
-
RATIONALE-315: Neoadjuvant Tislelizumab + Chemo in Resectable NSCLC – ESMO 2024 Results
-
12:17
Dr. Ben Park on ctDNA: Precision Oncology in Breast Cancer at SABCS 2024
-
ALNEO Trial: Neoadjuvant Alectinib in Resectable Stage III ALK+ NSCLC – WCLC 2024 Interim Data.
-
09:07
Cardiology for Beginners: Basics of Heart Sounds and Murmurs (with examples)
-
13:45
How to Become a Cardiologist | Cardiac Electrophysiologist
-
04:14
V 00592 Cardiology Fellowship Video Dr Vranian V5
-
05:17
Cardiology Fellowship at SIU Medicine
-
04:15
Cardiology Fellowship Program at Danbury Hospital
-
05:49
Practice Question: Cardiology #1, USMLE Step 1, COMLEX Level 1
-
04:07
Dr. Muhammed Raza on advice for Fellows interested in Interventional Cardiology
-
07:36
Congenital Heart Disease – Cardiology | Lecturio
-
05:18
Cardiology Fellowship at IU School of Medicine
-
04:36
What are different types of Cardiology Tests | SPS Hospitals
